Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Novosibirsk Scientists attempt to raise funds for the second phase of anti-parkinsonian drug trials
- By Newsdesk
- Russia
- Apr 27, 2023
Prottermin, a Parkinson's disease drug developed at the SB RAS's Novosibirsk Institute of Organic Chemistry named after N. N. Vorozhtsov (NIOH), completed the first phase of clinical trials in 2022. The outcome was encouraging: the drug demonstrated strong antiparkinsonian activity. Nonetheless, the second phase has yet to begin due to a lack of funding, according to Interfax.
According to Nariman Salakhutdinov, head of the NIOH laboratory of physiologically active substances, funding for the first phase of clinical trials was provided by a Novosibirsk businessman with Parkinson's disease, but "now no sources like that are available."
The researcher stated that the trials would require 400 million rubles. The Russian Federation's Ministry of Health has received documents for the second phase of drug trials.
The only drug available in Russia for the treatment of Parkinson's disease at the moment is Levodopa, which has several significant drawbacks with the main issue being its effectiveness starts to decline after three or four years of use.